Biotech startups that raised Series A in Asia
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| altM | Bangalore | Series A | $10.3M | 2026-11-05 |
| Apollon | Seoul | Series A | $3.7M | 2026-09-22 |
| Remepy | Ramat Gan | Series A | $36.0M | 2026-08-12 |
| Phil Rivers Technology | Beijing | Series A | $29.6M | 2026-08-05 |
| Tianhu Technology | Minhang | Series A | $29.0M | 2026-07-13 |
| SynMetaBio | Shanghai | Series A | $14.7M | 2026-07-06 |
| Prime Lifescience | Hangzhou | Series A | $14.7M | 2026-06-30 |
| Lingtai Krypton Biotechnology | Shuangliu | Series A | $13.7M | 2026-06-26 |
8 rows of the CSV in 5 of its 18 columns.
- The 721 biotech startups in Asia whose last round is Series A have raised $7.9B in total.
- 127 of them closed their most recent round in the last 12 months, $1.6B combined.
- The largest of those rounds is Anew Labs' $290.0M Series A, dated September 2026.
- The most recent is Afana Biotechnology's $50.0M Series A on 6 November 2026.
- TIPS Program is an investor in 6 of them, more than any other fund.
- Health care is the most common other sector, with 582 companies (81%).
- 36% were founded in 2020 or later; the median founding year is 2018.
- The most common team size is 11 to 50 employees (51% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 721| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| altM | altM is an alternate materials company. | Biotech | Bangalore, India | Series A | $10.3M | 2026-11-05 | $13.8M | Omnivore, Theia Ventures, Thai Wah Ventures | 11 to 50 | 2022 |
| Apollon | Apollon develops noninvasive continuous glucose monitoring systems. | Artificial intelligence | Seoul, South Korea | Series A | $3.7M | 2026-09-22 | $6.4M | TIPS Program, KB Investment, TheVentures +2 | 11 to 50 | 2021 |
| Remepy | Remepy develops hybrid drugs that combine multiple therapeutic approaches for biotechnology research. | Artificial intelligence | Ramat Gan, Israel | Series A | $36.0M | 2026-08-12 | $51.0M | Samsung NEXT, NFX, Vine Ventures +2 | 11 to 50 | 2022 |
| Phil Rivers Technology | Phil Rivers Technology provides AI solutions for pharmaceutical research and development. | Artificial intelligence | Beijing, China | Series A | $29.6M | 2026-08-05 | $57.3M | Insight Capital | 51 to 100 | 2015 |
| Tianhu Technology | Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. | Artificial intelligence | Minhang, China | Series A | $29.0M | 2026-07-13 | $54.2M | Qiming Venture Partners, GSR United Capital, 3E Bioventures | 11 to 50 | 2021 |
| SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Shanghai, China | Series A | $14.7M | 2026-07-06 | $16.1M | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2021 |
| Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Hangzhou, China | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| Lingtai Krypton Biotechnology | Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. | Biotech | Shuangliu, China | Series A | $13.7M | 2026-06-26 | $13.7M | Legend Capital, Guosheng Capital, Firefly Haoyue | 11 to 50 | 2021 |
| Artivila Therapeutics | Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. | Artificial intelligence | Shenzhen, China | Series A | $14.7M | 2026-06-23 | $53.3M | Highlight Capital, Med-Fine Capital, Hike Capital +2 | 11 to 50 | 2018 |
| MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian, China | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
| Dioseve | Dioseve produces egg cells using DIOLs to create more reproductive possibilities. | Biotech | Tokyo, Japan | Series A | $6.2M | 2026-06-11 | $15.5M | ANRI, Coral Capital, Archetype Ventures +2 | 11 to 50 | 2021 |
| Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Shanghai, China | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| Shanmu SHANMU | Shanmu develops micro medical robots using digital microfluidic chipsets and artificial intelligence algorithms. | Artificial intelligence | Shenzhen, China | Series A | $14.7M | 2026-05-06 | $16.0M | QF Capital, Hofan Venture, Wanwu Capital +1 | 1 to 10 | 2020 |
| Scala Biodesign | Scala Biodesign provides partners with a computational solution that increases the value of proteins and speeds their development. | Artificial intelligence | Tel Aviv, Israel | Series A | $16.0M | 2026-03-31 | $26.2M | Intel Capital, Intel Ignite, TLV Partners | 1 to 10 | 2022 |
| Neurodome | Neurodome manufactures non-invasive deep brain nerve modulation technology and products. | Biotech | Xian Shi, China | Series A | $14.5M | 2026-03-12 | $14.5M | Shunwei Capital, Frees Fund, Oriza Holdings +2 | 11 to 50 | 2019 |
| Celloid | Celloid supplies a 3D cell culture medium that supports quality-controlled long-term cultivation of organoids. | Biotech | Seongnam, South Korea | Series A | $6.1M | 2026-03-12 | $7.9M | FuturePlay, POSTECH Holdings | 1 to 10 | 2021 |
| iCamumo | iCamumo develops off-the-shelf, general-purpose cell therapies using iPSCs. | Biotech | Suzhou, China | Series A | $14.4M | 2026-03-09 | $75.2M | Delian Capital, West Lake Science and Technology Direct Investment Fund, Zhiyi Investment | 51 to 100 | 2021 |
| UniXell Biotechnology | UniXell Biotechnology develops cell therapy drugs. | Biotech | Pudong, China | Series A | $7.2M | 2026-02-11 | $52.5M | Hillhouse Investment, CDH Investments, Sherpa Healthcare Partners +1 | 11 to 50 | 2021 |
| Xingsai Bio | Xingsai Bio develops single-cell analysis instruments and related reagents and consumables. | Biotech | Qingdao Shi, China | Series A | $14.4M | 2026-01-19 | $28.3M | Hengxu Capital, Haitang Fund, Neovision Capital +1 | 51 to 100 | 2014 |
| Dishi Medical | Dishi Medical manufactures ophthalmic medical devices and micro-assisted robots supported by biotechnology. | Biotech | Hangzhou, China | Series A | $13.7M | 2026-01-19 | $13.7M | Hillhouse Investment, Fortune Venture Capital, Linear Capital +1 | 11 to 50 | 2021 |
| Huixin Medical Valley | Huixin Medical Valley develops cell therapies for neurological illnesses as a biopharmaceutical company. | Biotech | Changping, China | Series A | $14.3M | 2026-01-07 | $14.3M | Green Pine Capital Partners, Jiuzhi Ziben, Beijing Venture Capital | 51 to 100 | 2021 |
| PRCXI Biotechnology | PRCXI Biotechnology provides analytical instruments, bioinformatics, and automation solutions for life sciences. | Biotech | Suzhou, China | Series A | $14.0M | 2025-12-31 | $55.0M | Qiming Venture Partners, SAIF Partners | 101 to 250 | 2014 |
| Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Shanghai, China | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| Ningkang Ruizhu | Ningkang Ruizhu develops targeted drugs. | Biotech | Zhuhai, China | Series A | $14.1M | 2025-12-05 | $25.6M | GF Qianhe Investment, RiverHead Capital, Hanne Capital +1 | 11 to 50 | 2019 |
| immunitoAI | ImmunitoAI is a biotech platform that applies AI to antibody discovery and therapeutics. | Biotech | Bangalore, India | Series A | $6.1M | 2025-11-25 | $7.1M | Pi Ventures | 11 to 50 | 2020 |
| Kunshi Biotechnology | Kunshi Biotechnology develops drugs with an emphasis on solid tumor cells. | Biotech | Suzhou, China | Series A | $7.0M | 2025-11-20 | $7.0M | Deshi Capital | 51 to 100 | 2021 |
| Brise Pharma | Brise Pharma provides scientific research and technical services in the pharmaceutical field. | Biotech | Shanghai, China | Series A | $28.1M | 2025-11-11 | $228.3M | Qiming Venture Partners, Sherpa Healthcare Partners, BioTrack Capital +1 | 11 to 50 | 2021 |
| Primo Biotechnology | Primo Biotechnology develops precision medicine and radioligand theranostics for cancer treatment. | Artificial intelligence | Taipei, Taiwan | Series A | $7.6M | 2025-07-02 | $14.1M | AVA Angels | 11 to 50 | 2023 |
| Cure Stream | Cure Stream develops an autonomous artificial pancreas system that uses an AI algorithm to decide hormone injections. | Artificial intelligence | Daegu, South Korea | Series A | $7.8M | 2025-05-14 | $7.8M | TIPS Program | 2019 | |
| Wimi bio | Wimi Bio researches and develops gene editing and biological breeding technologies as a high-tech enterprise. | Biotech | Nanjing, China | Series A | $14.1M | 2024-09-19 | HosenCare Brothers | 51 to 100 | 2017 |
Table 1. Biotech startups that raised Series A in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 721.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MoleculeMind | MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. | Artificial intelligence | Haidian, China | Series A | $86.0M | 2026-06-17 | $114.6M | Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital | 51 to 100 | 2022 |
| 2 | Allink Biotherapeutics | Allink Biotherapeutics develops multi-specific antibodies for treating cancer and immune disorders. | Biotech | Shanghai, China | Series A | $47.0M | 2025-12-16 | $89.0M | Legend Capital, Gaorong Capital, BioVenture +2 | 11 to 50 | 2023 |
| 3 | Degron Therapeutics | Degron Therapeutics discovers molecular glue degraders for cancer treatment. | Biotech | Shanghai, China | Series A | $40.0M | 2026-05-14 | $94.0M | Baidu Ventures, BioVenture, New Alliance Capital +2 | 101 to 250 | 2021 |
| 4 | Remepy | Remepy develops hybrid drugs that combine multiple therapeutic approaches for biotechnology research. | Artificial intelligence | Ramat Gan, Israel | Series A | $36.0M | 2026-08-12 | $51.0M | Samsung NEXT, NFX, Vine Ventures +2 | 11 to 50 | 2022 |
| 5 | Phil Rivers Technology | Phil Rivers Technology provides AI solutions for pharmaceutical research and development. | Artificial intelligence | Beijing, China | Series A | $29.6M | 2026-08-05 | $57.3M | Insight Capital | 51 to 100 | 2015 |
| 6 | Tianhu Technology | Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. | Artificial intelligence | Minhang, China | Series A | $29.0M | 2026-07-13 | $54.2M | Qiming Venture Partners, GSR United Capital, 3E Bioventures | 11 to 50 | 2021 |
| 7 | Scala Biodesign | Scala Biodesign provides partners with a computational solution that increases the value of proteins and speeds their development. | Artificial intelligence | Tel Aviv, Israel | Series A | $16.0M | 2026-03-31 | $26.2M | Intel Capital, Intel Ignite, TLV Partners | 1 to 10 | 2022 |
| 8 | Artivila Therapeutics | Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. | Artificial intelligence | Shenzhen, China | Series A | $14.7M | 2026-06-23 | $53.3M | Highlight Capital, Med-Fine Capital, Hike Capital +2 | 11 to 50 | 2018 |
| 9 | Prime Lifescience | Prime Lifescience develops a big data platform for life sciences research and analysis. | Biotech | Hangzhou, China | Series A | $14.7M | 2026-06-30 | $44.5M | Qiming Venture Partners, Qiji Investment, Ennovation Ventures | 11 to 50 | 2021 |
| 10 | SynMetaBio | SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. | Biotech | Shanghai, China | Series A | $14.7M | 2026-07-06 | $16.1M | MiraclePlus, Linear Capital, Danen Capital | 11 to 50 | 2021 |
Table 2. Biotech startups that raised Series A in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | TIPS Program | Startup incubator | Gangneung, South Korea | 6 | 1% | 1 | Apollon |
| 2 | BioVenture | Venture capital firm | Suzhou, China | 6 | 1% | 2 | Degron Therapeutics, Allink Biotherapeutics |
| 3 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 5 | 1% | 3 | Tianhu Technology, Prime Lifescience, PRCXI Biotechnology |
| 4 | CDH Investments | Private equity firm | Kowloon City, Hong Kong | 4 | 1% | 1 | UniXell Biotechnology |
| 5 | Gaorong Capital | Venture capital firm | Wangjing, China | 3 | 0% | 2 | BioGeometry, Allink Biotherapeutics |
| 6 | KB Investment | Private equity firm | Seoul, South Korea | 3 | 0% | 1 | Apollon |
| 7 | Legend Capital | Venture capital firm | Beijing, China | 3 | 0% | 2 | Lingtai Krypton Biotechnology, Allink Biotherapeutics |
| 8 | ANRI | Venture capital firm | Tokyo, Japan | 3 | 0% | 2 | Dioseve, Cosomil |
| 9 | Frees Fund | Venture capital firm | Beijing, China | 3 | 0% | 1 | Neurodome |
| 10 | Shaanxi Investment Capital | Venture capital firm | Xian, China | 3 | 0% | 1 | Neurodome |
| 11 | Hillhouse Investment | Angel group | Singapore | 3 | 0% | 2 | UniXell Biotechnology, Dishi Medical |
| 12 | SZHTI Group | Venture capital firm | Shenzhen, China | 3 | 0% | 2 | Newdel Biotech, JGene Biotechnology |
| 13 | Haitang Fund | Venture capital firm | Nankai, China | 3 | 0% | 1 | Xingsai Bio |
| 14 | Taiyu Investment | Venture capital firm | Beijing, China | 3 | 0% | ||
| 15 | Bluepoint | Startup accelerator | Daejeon, South Korea | 3 | 0% |
Table 3. Biotech startups that raised Series A in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 582 | 81% | $7.0B |
| Software | 61 | 8% | $1.0B |
| Artificial intelligence | 42 | 6% | $975.8M |
| Hardware | 26 | 4% | $82.3M |
| Cybersecurity | 9 | 1% | |
| Energy | 4 | 1% | $61.8M |
| Commerce | 3 | 0% | |
| Fintech | 3 | 0% | |
| Education | 2 | 0% |
Table 4. Biotech startups that raised Series A in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 721 | 100% | $8.1M |
Table 5. Biotech startups that raised Series A in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| China | 485 | 67% |
| South Korea | 84 | 12% |
| Israel | 42 | 6% |
| Japan | 41 | 6% |
| Singapore | 25 | 3% |
| India | 17 | 2% |
| Taiwan | 12 | 2% |
| Hong Kong | 8 | 1% |
| Sri Lanka | 3 | 0% |
| United Arab Emirates | 1 | 0% |
| Malaysia | 1 | 0% |
| Turkey | 1 | 0% |
Table 6. Biotech startups that raised Series A in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
Table 7. Biotech startups that raised Series A in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 4 | 3% | $60.3M |
| October 2026 | 9 | 7% | $91.2M |
| September 2026 | 6 | 5% | $314.7M |
| August 2026 | 14 | 11% | $198.9M |
| July 2026 | 15 | 12% | $166.3M |
| June 2026 | 7 | 6% | $171.4M |
| May 2026 | 12 | 9% | $156.3M |
| April 2026 | 5 | 4% | $55.7M |
| March 2026 | 7 | 6% | $51.1M |
| February 2026 | 7 | 6% | $39.7M |
| January 2026 | 18 | 14% | $94.6M |
| December 2025 | 14 | 11% | $196.3M |
| November 2025 | 9 | 7% | $42.7M |
Table 8. Biotech startups that raised Series A in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 104 | 14% | $1.4B |
| 2025 | 103 | 14% | $975.1M |
| 2024 | 96 | 13% | $588.2M |
| 2023 | 90 | 12% | $860.1M |
| 2022 | 69 | 10% | $1.1B |
| 2021 | 66 | 9% | $923.3M |
Table 9. Biotech startups that raised Series A in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 32 | 5% |
| 2020 to 2022 | 221 | 31% |
| 2015 to 2019 | 289 | 41% |
| 2010 to 2014 | 98 | 14% |
| Before 2010 | 67 | 9% |
Table 10. Biotech startups that raised Series A in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 101 | 17% |
| 11 to 50 | 297 | 51% |
| 51 to 100 | 96 | 16% |
| 101 to 250 | 46 | 8% |
| 251 to 500 | 21 | 4% |
| 501 to 1,000 | 9 | 2% |
| 1,001 to 5,000 | 9 | 2% |
| 5,001 to 10,000 | 1 | 0% |
| 10,001 or more | 2 | 0% |
Table 11. Biotech startups that raised Series A in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in Asia. On 16 November 2026 that is 721 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 721 rows: 235 have no round amount, 0 no city and 265 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Asia whose last round is Series A are on the list?
- 721, in the file dated 16 November 2026. 127 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 721 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.